Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review

Journal of Pain and Symptom Management

Volumn 25, Issue 6, 2003, Pages 559-577

  Fishbain, David A ^a,b,c   Cutler, R Brian ^a,b   Rosomoff, Hubert L ^a,b   Rosomoff, Renee Steele ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c NONE   (United States)

Author keywords

Cognitive impairment; Driving; Evidence based review; Motor vehicle accidents; Opiates; Opioid tolerance; Opioids; Psychomotor performance; Reaction times; Structured review

Indexed keywords

HYDROMORPHONE; METHADONE; NALBUPHINE; OPIATE;

COGNITION; DRIVING ABILITY; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; LITERATURE; MOTOR PERFORMANCE; NEUROTOXICITY; OPIATE ADDICTION; QUANTITATIVE ANALYSIS; REVIEW; TASK PERFORMANCE; TRAFFIC ACCIDENT;

EID: 0038751575     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(03)00176-3     Document Type: Review

References (74)

1. Weiler J.M., Bloomfield J.R., Woodworth G.G., Gant A.R., Layton T.A. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. Ann Intern Med. 132:2000;354-363.
2. Blanke R.V., Caplan Y.H., Chamberlaine R.T., Dubowski K.M., Finkle S. Drug concentrations and driving impairment. JAMA. 254:(18):1985;2618-2621.
3. Belly L. Drugs and medicines in medical aspects of fitness to drive, a guide for medical practitioners. 1995;Medical Commission on Accident Prevention, U.K.
4. Joo S. Methadone substitution and driver ability: research findings and conclusions from a discussion of experts. J Traffic Med. 22:(3):1994;101-103.
5. Zacny J. Should people taking opioids for medical reasons be allowed to work and drive? Addiction. 91:(11):1996;1581-1584.
6. Smith A.M. Patients taking stable doses of morphine may drive. BMJ. 312:(6 Jan):1996;56-57.
7. Perry C.J.G., Morgenstern A.L. Drugs and driving. JAMA. 195:(5):1966;376-379.
8. Chesher G.B. The influence of analgesic drugs in road crashes. Accid Anal Prev. 17:(4):1985;303-309.
9. Haythornthwaite J.A., Menefee L.A., Quatrano-Piacentini A.L., Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage. 15:(3):1998;185-194.
10. Seppela T., Linnoila M., Mattila J.J. Drugs, alcohol and driving. Drugs. 17:1979;389-408.
11. Zacny J. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exper Clin Psychopharma. 3:(4):1995;432-466.
12. Payne R. Medication induced performance deficits: analgesics and narcotics. J Ocup Med. 32:1980;362-369.
13. Roth T., Roehrs T.A., Moskowitz H. Issues in drug-related performance impairment. Clin Therapeutics. 14:(5):1992;654-666.
14. O'Neill W. The cognitive and psychomotor effects of opioid drugs in cancer pain management. Cancer Surveys. 21:1994;67-84.
15. Gordon N. Influence of narcotic drugs on highway safety. Accid Anal Prev. 8:1976;3-7.
16. Fishbain D.A., Cutler R.B., Rosomoff H.L., Steele-Rosomoff R. Can patients taking opioids drive safely? A structured evidence-based review. Pain & Palliative Care Pharmacotherapy. 16:(1):2002;9-28.
17. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice. Clinical practice guidelines: directions for a new program. 1990;National Academy Press, Washington DC.
18. Appel P.W. Sustained attention in methadone patients. Int J Addict. 17:(8):1982;1313-1327.
19. Gordon N.B. Reaction times of methadone-treated heroin addicts. Psychopharmacologia. 16:1970;337-344.
20. Banning A., Sjøgren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clinical J Pain. 6:1990;91-95.
21. Rossler H., Battista H.J., Deisenhammer F., et al. Methadone-substitution and driving ability. Forensic Science International. 62:(1-2):1993;63-66.
22. Sjøgren P., Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain. 39:(1):1989;5-11.
23. Rothenberg S., Schottenfield S., Meyer R.E., Kraus B., Gross K. Performance differences between addicts and non-addicts. Psychopharmacology. 52:1977;299-306.
24. Sjøgren P., Banning A.M., Christensen C.B., Pedersen O. Continuous reaction time after single dose, long-term oral and epidural opioid administration. Eur J Anaesthesiology. 11:(2):1994;95-100.
25. Moskowitz H., Robinson C.D. Methadone maintenance and tracking performance. Kay S., Meier G.W. Proc Ninth Intl. Conf. On Alcohol, Drugs and Traffic Safety - San Juan, PR 1983. 1985;995-1004 U.S. Department of Transportation, National Highway Traffic Safety Administration, US Government Printing Office.
26. Robinson CD, Moskowitz H. Methadone maintenance treatment and aspects of skilled performance in alcohol, drugs and traffic safety. Proceedings of the Ninth International Conference on Alcohol, Drugs and Traffic Safety-San Juan, PR. 1983; Kaye S, Meier GW, eds., San Juan, PR: 1983;1145-1157.
27. Specka M., Finkbeiner T., Lodemann E., et al. Cognitive-motor performance of methadone-maintained patients. Euro Addict Res. 6:2000;8-19.
28. Appel P., Gordon N. Digit-symbol performance in methadone-treated ex-heroin addicts. Am J Psychiatry. 133:1976;1337-1339.
29. Gerhard U., Ladewig D., Hobi V. Cognitive-psychomotor capability of heroin addicts. Neurol Psychiatr. 3:1989;489-496.
30. Staak M., Berghaus G., Glazinski R., et al. Empirische untersuchungen zur fahreignun von methadon-substitutions-patienten (Experimental research on driver fitness of methadone-substituted heroin addicts). Blutalkohol. 30:1993;321-333.
31. Hornung P., Poehike T., Sproedt J., Köhler-Schmidt H. Levomethadone-substitution and driving fitness. Sucht. 42:1996;92-97.
32. Kubitzki J. Charakteristische merkmale der kraftfahrtauglichkeit von methadonpatienten. Berichte der Bundesanstalt für Strassenwesen. 1997;Bundesanstalt für Strassenwesen, Bergisch Gladbach. M76.
33. Vainio A., Ollila J., Matikainen E., Rosenberg P., Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet. 346:(8976):1995;667-670.
34. Lombardo W., Lombardo B., Goldstein A. Cognitive functioning under moderate and low dosage methadone maintenance. Int J. 11:(3):1976;389-401.
35. Clemons M., Regnard C., Appleton T. Alertness, cognition and morphine in patients with advanced cancer. Cancer Treatment Reviews. 22:(6):1996;451-468.
36. Wood M.M., Ashby M.A., Somogyi A.A., Fleming B.G. Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. J Pain Symptom Manage. 16:(2):1998;112-120.
37. Kelley D., Welch R., McKnelley W. Methadone Maintenance: An assessment of potential fluctua-tions in behavior between doses. Int J Addict. 13:(7):1978;1061-1068.
38. Strain E.C., Walsh S.L., Preston K.L., Liebson I.A., Bigelow G.E. The effects buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology. 129:(4):1997;329-338.
39. Bruera E., Macmillan K., Hanson J., MacDonald N. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 39:1989;13-16.
40. Blomberg R.D., Preusser D.F. Narcotic use and driving behavior. Accid Annal Prev. 6:1974;23-32.
41. Maddux J., Williams T.R., Ziegler J.A. Driving records before and during methadone maintenance. Amer J Drug & Alcohol Abuse. 4:(1):1977;91-100.
42. Babst D.U., Newman S., Gordon N., Warner A. Driving records of methadone maintenance patients in New York State. J Drug Issues. (Fall):1973;285-292.
43. Berghaus G., Staak M., Glazinski R., et al. Complementary empirical study on the driver fitness of methadone substitution patients. Alcohol Drugs and Traffic Safety. 1993;Verlag Tuv Rheinland, Cologne, Germany. 120-126.
44. Galski T., Williams J., Ehle H. Effects of opioids on driving ability. J Symptom Manage. 19:(3):2000;200-208.
45. Chapman S. The effects of opioids on driving ability in patients with chronic pain. Am. Pain Society Bulletin. 11:(1):2001;1-5.
46. Sjøgren P., Olsen A.K., Thomsen A.B., Dalberg J. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain. 86:(3):2000;237-245.
47. Sjøgren P., Thomsen A.B., Olsen A.K. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage. 19:(2):2000;100-108.
48. Haythornthwaite J., Menefee L., Quatrano-Piacentini A., Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage. 15:(3):1998;185-194.
49. Preston K.L., Bigelow G.E., Bickel W., Warren L., Liebson I.A. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharm and Experimental Therapeutics. 243:(3):1987;1002-1009.
50. Preston K.L., Bigelow G.E., Liebson I.A. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharm Experimental Therapeutics. 246:(2):1988;441-448.
51. Preston K.L., Bigelow G.E., Liebson I.A. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharm Experimental Therapeutics. 248:(3):1989;929-937.
52. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharm Experimental Therapeutics. 261:(3):1992;985-993.
53. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharm Experimental Therapeutics. 272:(2):1995;628-638.
54. Strain E.C., Walsh S.L., Bigelow G.E. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology. 159:2002;161-166.
55. Moulin D.E., Lezzi A., Amireh R., et al. Randomized trial of oral morphine for chronic non-cancer pain. Lancet. 347:1996;143-147.
56. Gritz E.R., Shifrin S.M., Jarvik M.E., et al. Physiological and psychological effects of methadone in man. Arch Gen Psychiatry. 32:1975;137-242.
57. Drake S., Sims J., McDonald S., Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 95:(5):2000;687-695.
58. Comer S.D., Collins E.D., Fischman M.W. Choice between money and intranasal heroin in morphine-maintained humans. Behavioral Pharm. 8:1997;677-690.
59. Lodemann E., Keifert K., Kluwig J., Finkbeiner T., Gastpar M. Methadone maintenance and driving ability. Pharmacopsychiat. 28:1995;199.
60. Preston K.L., Bigelow G.E., Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology. 94:1988;484-490.
61. Preston K.L., Bigelow G.E., Bickel W.K., Liebson I.A. Drug discrimination in human post addicts; agonist-antagonist opioids. J Pharm Experimental Therapeutics. 250:(1):1989;184-196.
62. Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharm Therapeutics. 53:(5):1993;570-576.
63. Preston K.L., Liebson I.A., Bigelow G.E. The discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J Pharm Experimental Therapeutics. 261:(1):1992;62-71.
64. Staak M., Berghaus G., Glazinski R., et al. Empirical studies of automobile driving fitness of patients treated with methadone-substitution. Blutalkohol. 30:(6):1993;321-333.
65. Smart R., Fejer D. Drug use and driving risk among high school students. Accid Anal Prev. 8:1976;33-38.
66. Roth T., Moskowitz H. Issues in drug-related performance impairment. Clinical Therapeutics. 14:(5):1992;654-666.
67. Linton S.J. Occupational psychological factors increase the risk for back pain; a systematic review. J Occupational Rehabilitation. 1:(1):2001;53-65.
68. van Tulder M.W., Assendelft W.J.J., Koes B.W., Bouter L.M. Method guidelines for systematic review in Cochrane collaboration back review group for spinal disorders. Spine. 22:(20):1997;2323-2330.
69. Hoogendoorn W.E., van Poppel M.N.M., Bongers P.M., Koes B.W., Bouter L.M. Systematic review of psychosocial factors at work and in the personal situation as risk factors for back pain. Spine. 25:(16):2000;2114-2125.
70. Lorenz J., Beck H., Bromm B. Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain. Pain. 73:(3):1997;369-375.
71. Hanks G., Twycross R. Pain, the physiological antagonist of opioid analgesics. Lancet. 1:(June30):1984;1477-1478.
72. Hanks G. Morphine sans Morpheus. Lancet. 346:(Sept 9):1995;652-653.
73. Rounsaville B., Jones C., Novelly R., Kleber H. Neuropsychological functioning in opiate addicts. J Nervous & Mental Dis. 170:(4):1982;209-216.
74. Selby M.J., Azrin R.L. Neuropsychological functioning in drug abusers. Drug & Alcohol Dependence. 50:(1):1998;39-45.